1
NR566 Week 4 Midterm Exam Review Due September 28th
2025 Complete Questions 1-100 Actual Exam Examplify Online
Proctored Exam NR566 Advanced Pharmacology For Care Of
The Family Questions and Answers | 100% Pass Guaranteed |
Graded A+
NR566 Advanced Pharmacology for Care of the Family
100 Original Midterm Study Questions — Weeks 1–4 Comprehensive Review
Original Exam-Style Questions | Detailed Correct Answers | Organized by Body
System
Academic Integrity Notice: These are 100% original study questions written from
core NR566 curriculum learning objectives. They are NOT copied from any
proprietary exam, test bank, or copyrighted material. Use them as a rigorous
study tool alongside your course materials.
SECTION 1: PHARMACOLOGY FOUNDATIONS & PRESCRIBING PRINCIPLES (Q1–
12)
Q1. A family nurse practitioner is initiating a new medication for an elderly
patient with multiple comorbidities. Which pharmacokinetic parameter is MOST
significantly altered in older adults, increasing the risk of drug toxicity?
• A) Oral drug absorption via the GI tract
• B) Hepatic and renal clearance — reduced GFR and CYP450 activity
• C) Plasma protein binding — always increased in elderly
• D) Drug distribution into fatty tissue — always decreased
✅ Answer: B) Hepatic and renal clearance Reduced GFR (often undetected by
serum creatinine alone in older adults with low muscle mass) and diminished
pg. 1
,2
hepatic CYP450 activity are the most clinically significant PK changes. Use CKD-EPI
or Cockcroft-Gault equation to estimate GFR.
Q2. A patient is prescribed a medication that is a CYP3A4 substrate. She also
takes ketoconazole, a strong CYP3A4 inhibitor. What is the expected outcome?
• A) Reduced plasma levels of the substrate drug
• B) Increased plasma levels of the substrate — potential toxicity
• C) Increased metabolism and reduced therapeutic effect
• D) No clinically relevant interaction
✅ Answer: B) Increased plasma levels — potential toxicity CYP3A4 inhibition
slows metabolism of the substrate, raising plasma concentrations and increasing
risk of dose-dependent toxicity.
Q3. When prescribing medications in pregnancy, which resource provides the
most current evidence-based information on drug safety?
• A) The old FDA pregnancy Category A–X system
• B) The FDA Pregnancy and Lactation Labeling Rule (PLLR) with narrative
sections
• C) Package inserts from the 1990s
• D) Drug company websites exclusively
✅ Answer: B) FDA PLLR The PLLR (effective 2015) replaced the A–X categories
with narrative text covering pregnancy exposure registries, risk summaries, and
clinical considerations for pregnancy, lactation, and reproductive potential.
Q4. The NP is reviewing a patient's medication list using the Beers Criteria. This
tool is primarily designed to:
• A) Calculate maximum allowable doses for all adults
pg. 2
,3
• B) Identify potentially inappropriate medications in adults aged ≥65
• C) Screen for controlled substance abuse in all patients
• D) Guide renal dosing adjustments
✅ Answer: B) Identify potentially inappropriate medications in adults ≥65
Q5. A prescriber writes for metformin 500 mg PO BID. The abbreviation "BID"
means the medication should be taken:
• A) Once daily
• B) Twice daily
• C) Three times daily
• D) Every 8 hours
✅ Answer: B) Twice daily
Q6. Narrow therapeutic index (NTI) drugs require the most careful monitoring
because:
• A) They are rarely effective at any dose
• B) The toxic dose is very close to the therapeutic dose — small changes
cause significant harm
• C) They always have many drug interactions
• D) They are poorly absorbed orally
✅ Answer: B) Toxic dose close to therapeutic dose Examples: warfarin, digoxin,
lithium, phenytoin, theophylline.
Q7. A patient reports taking St. John's Wort for depression. The NP is concerned
because St. John's Wort:
• A) Inhibits CYP3A4, raising levels of other medications
pg. 3
, 4
• B) Induces CYP3A4 and P-glycoprotein — reducing levels of oral
contraceptives, antiretrovirals, and warfarin
• C) Blocks serotonin reuptake without any drug interactions
• D) Has no pharmacological activity
✅ Answer: B) CYP3A4 inducer — reduces levels of many drugs Can reduce OCP
efficacy (pregnancy risk), lower INR in warfarin patients, and reduce antiretroviral
levels.
Q8. Which principle best describes pharmacodynamic tolerance?
• A) A drug is eliminated more quickly with repeated use
• B) The body's receptors become less sensitive with repeated drug
exposure, requiring higher doses for the same effect
• C) A drug becomes more bioavailable over time
• D) A drug's half-life shortens with repeated dosing
✅ Answer: B) Receptor desensitization requiring higher doses
Q9. A patient is a CYP2D6 ultra-rapid metabolizer. She is prescribed codeine for
pain. The primary safety concern is:
• A) Insufficient analgesia due to rapid elimination
• B) Conversion of codeine to morphine occurs too rapidly — risk of opioid
toxicity and respiratory depression
• C) Reduced first-pass effect
• D) Increased risk of serotonin syndrome
✅ Answer: B) Ultra-rapid conversion to morphine — opioid toxicity risk The
FDA warns against codeine in ultra-rapid CYP2D6 metabolizers and breastfeeding
mothers for this reason.
pg. 4
NR566 Week 4 Midterm Exam Review Due September 28th
2025 Complete Questions 1-100 Actual Exam Examplify Online
Proctored Exam NR566 Advanced Pharmacology For Care Of
The Family Questions and Answers | 100% Pass Guaranteed |
Graded A+
NR566 Advanced Pharmacology for Care of the Family
100 Original Midterm Study Questions — Weeks 1–4 Comprehensive Review
Original Exam-Style Questions | Detailed Correct Answers | Organized by Body
System
Academic Integrity Notice: These are 100% original study questions written from
core NR566 curriculum learning objectives. They are NOT copied from any
proprietary exam, test bank, or copyrighted material. Use them as a rigorous
study tool alongside your course materials.
SECTION 1: PHARMACOLOGY FOUNDATIONS & PRESCRIBING PRINCIPLES (Q1–
12)
Q1. A family nurse practitioner is initiating a new medication for an elderly
patient with multiple comorbidities. Which pharmacokinetic parameter is MOST
significantly altered in older adults, increasing the risk of drug toxicity?
• A) Oral drug absorption via the GI tract
• B) Hepatic and renal clearance — reduced GFR and CYP450 activity
• C) Plasma protein binding — always increased in elderly
• D) Drug distribution into fatty tissue — always decreased
✅ Answer: B) Hepatic and renal clearance Reduced GFR (often undetected by
serum creatinine alone in older adults with low muscle mass) and diminished
pg. 1
,2
hepatic CYP450 activity are the most clinically significant PK changes. Use CKD-EPI
or Cockcroft-Gault equation to estimate GFR.
Q2. A patient is prescribed a medication that is a CYP3A4 substrate. She also
takes ketoconazole, a strong CYP3A4 inhibitor. What is the expected outcome?
• A) Reduced plasma levels of the substrate drug
• B) Increased plasma levels of the substrate — potential toxicity
• C) Increased metabolism and reduced therapeutic effect
• D) No clinically relevant interaction
✅ Answer: B) Increased plasma levels — potential toxicity CYP3A4 inhibition
slows metabolism of the substrate, raising plasma concentrations and increasing
risk of dose-dependent toxicity.
Q3. When prescribing medications in pregnancy, which resource provides the
most current evidence-based information on drug safety?
• A) The old FDA pregnancy Category A–X system
• B) The FDA Pregnancy and Lactation Labeling Rule (PLLR) with narrative
sections
• C) Package inserts from the 1990s
• D) Drug company websites exclusively
✅ Answer: B) FDA PLLR The PLLR (effective 2015) replaced the A–X categories
with narrative text covering pregnancy exposure registries, risk summaries, and
clinical considerations for pregnancy, lactation, and reproductive potential.
Q4. The NP is reviewing a patient's medication list using the Beers Criteria. This
tool is primarily designed to:
• A) Calculate maximum allowable doses for all adults
pg. 2
,3
• B) Identify potentially inappropriate medications in adults aged ≥65
• C) Screen for controlled substance abuse in all patients
• D) Guide renal dosing adjustments
✅ Answer: B) Identify potentially inappropriate medications in adults ≥65
Q5. A prescriber writes for metformin 500 mg PO BID. The abbreviation "BID"
means the medication should be taken:
• A) Once daily
• B) Twice daily
• C) Three times daily
• D) Every 8 hours
✅ Answer: B) Twice daily
Q6. Narrow therapeutic index (NTI) drugs require the most careful monitoring
because:
• A) They are rarely effective at any dose
• B) The toxic dose is very close to the therapeutic dose — small changes
cause significant harm
• C) They always have many drug interactions
• D) They are poorly absorbed orally
✅ Answer: B) Toxic dose close to therapeutic dose Examples: warfarin, digoxin,
lithium, phenytoin, theophylline.
Q7. A patient reports taking St. John's Wort for depression. The NP is concerned
because St. John's Wort:
• A) Inhibits CYP3A4, raising levels of other medications
pg. 3
, 4
• B) Induces CYP3A4 and P-glycoprotein — reducing levels of oral
contraceptives, antiretrovirals, and warfarin
• C) Blocks serotonin reuptake without any drug interactions
• D) Has no pharmacological activity
✅ Answer: B) CYP3A4 inducer — reduces levels of many drugs Can reduce OCP
efficacy (pregnancy risk), lower INR in warfarin patients, and reduce antiretroviral
levels.
Q8. Which principle best describes pharmacodynamic tolerance?
• A) A drug is eliminated more quickly with repeated use
• B) The body's receptors become less sensitive with repeated drug
exposure, requiring higher doses for the same effect
• C) A drug becomes more bioavailable over time
• D) A drug's half-life shortens with repeated dosing
✅ Answer: B) Receptor desensitization requiring higher doses
Q9. A patient is a CYP2D6 ultra-rapid metabolizer. She is prescribed codeine for
pain. The primary safety concern is:
• A) Insufficient analgesia due to rapid elimination
• B) Conversion of codeine to morphine occurs too rapidly — risk of opioid
toxicity and respiratory depression
• C) Reduced first-pass effect
• D) Increased risk of serotonin syndrome
✅ Answer: B) Ultra-rapid conversion to morphine — opioid toxicity risk The
FDA warns against codeine in ultra-rapid CYP2D6 metabolizers and breastfeeding
mothers for this reason.
pg. 4
